Download
41375_2024_Article_2231.pdf 794,91KB
WeightNameValue
1000 Titel
  • Radiotherapy in younger patients with advanced aggressive B-cell lymphoma—long-term results from the phase 3 R-MegaCHOEP trial
1000 Autor/in
  1. Oertel, Michael |
  2. Ziepert, Marita |
  3. Frontzek, Fabian |
  4. Nacke, Nina |
  5. Altmann, Bettina |
  6. Nickelsen, Maike |
  7. Glass, Bertram |
  8. Poeschel, Viola |
  9. Ruebe, Christian |
  10. Lenz, Georg |
  11. Schmitz, Norbert |
  12. Eich, Hans Theodor |
1000 Verlag Nature Publishing Group UK
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-03-27
1000 Erschienen in
1000 Quellenangabe
  • 38(5):1099-1106
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41375-024-02231-9 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11073960/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:p>The role of consolidative radiotherapy (RT) for patients with aggressive B-cell lymphoma has not been fully elucidated. The R-MegaCHOEP trial investigated the use of high-dose chemotherapy and rituximab with subsequent autologous stem cell transplantations compared to conventional immunochemotherapy (R-CHOEP) for high-risk patients up to 60 years. The study protocol included RT for patients with bulky (maximum diameter ≥7.5 cm) or extranodal disease. Two-hundred sixty-one patients were analyzed, 120 of whom underwent RT. The most frequently irradiated regions were mediastinum (<jats:italic>n</jats:italic> = 50) and paraaortic (<jats:italic>n</jats:italic> = 27). Median RT dose was 36 Gray in median fractions of 1.8 Gray. Acute toxicities were mostly mild to moderate, with only 24 and 8 grade 3 and 4 toxicities reported during RT. Patients with bulky disease who received RT showed significantly better 10-year EFS, PFS and OS (EFS: 64% vs. 35%; <jats:italic>p</jats:italic> &lt; 0.001; PFS 68% vs. 47%; <jats:italic>p</jats:italic> = 0.003; OS: 72% vs. 59%; <jats:italic>p</jats:italic> = 0.011). There was no significant increase in secondary malignancies with the use of RT. RT administered for consolidation of bulky disease after immunochemotherapy improved the prognosis of young high-risk patients with aggressive B-cell lymphoma and should be considered part of first-line therapy. The <jats:italic>trial was registered with ClinicalTrials.gov, number NCT00129090</jats:italic>.</jats:p>
1000 Sacherschließung
lokal Adolescent [MeSH]
lokal Female [MeSH]
lokal Follow-Up Studies [MeSH]
lokal /692/699/67/1059/485
lokal Lymphoma, B-Cell/therapy [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Middle Aged [MeSH]
lokal Lymphoma, B-Cell/mortality [MeSH]
lokal Lymphoma, B-Cell/radiotherapy [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH]
lokal Rituximab/administration
lokal Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH]
lokal Survival Rate [MeSH]
lokal Rituximab/therapeutic use [MeSH]
lokal Article
lokal Male [MeSH]
lokal /692/699/67/1059/99
lokal Prognosis [MeSH]
lokal Young Adult [MeSH]
lokal Hematopoietic Stem Cell Transplantation/methods [MeSH]
lokal Combined Modality Therapy [MeSH]
lokal Lymphoma, B-Cell/pathology [MeSH]
lokal article
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-2786-7013|https://frl.publisso.de/adhoc/uri/WmllcGVydCwgTWFyaXRh|https://orcid.org/0000-0003-1705-3638|https://frl.publisso.de/adhoc/uri/TmFja2UsIE5pbmE=|https://frl.publisso.de/adhoc/uri/QWx0bWFubiwgQmV0dGluYQ==|https://frl.publisso.de/adhoc/uri/Tmlja2Vsc2VuLCBNYWlrZQ==|https://orcid.org/0000-0003-2583-6333|https://frl.publisso.de/adhoc/uri/UG9lc2NoZWwsIFZpb2xh|https://frl.publisso.de/adhoc/uri/UnVlYmUsIENocmlzdGlhbg==|https://orcid.org/0000-0002-4728-1693|https://orcid.org/0000-0003-4938-7528|https://frl.publisso.de/adhoc/uri/RWljaCwgSGFucyBUaGVvZG9y
1000 Hinweis
  • DeepGreen-ID: eadfd1e2f1334f5e8dca28c76de4fef4 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6492691.rdf
1000 Erstellt am 2025-02-03T18:31:54.457+0100
1000 Erstellt von 322
1000 beschreibt frl:6492691
1000 Zuletzt bearbeitet 2025-09-13T06:06:26.355+0200
1000 Objekt bearb. Sat Sep 13 06:06:26 CEST 2025
1000 Vgl. frl:6492691
1000 Oai Id
  1. oai:frl.publisso.de:frl:6492691 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source